Last updated: February 25, 2026
What is the scope of patent DK1761266?
Patent DK1761266 covers a specific pharmaceutical formulation or method related to a designated active ingredient or combination. The scope is defined by the patent claims, which specify the inventive subject matter protected. The patent focuses on [specific drug or therapeutic use], likely involving a unique composition, delivery mechanism, or method of treatment.
The patent's claims aim to prevent third parties from manufacturing, using, selling, or importing identical or equivalent inventions within Denmark. The scope hinges on the language of the independent claims, typically broad in covering the core inventive concept, with dependent claims narrowing down specific embodiments.
What are the key claims of DK1761266?
Independent Claims
Most patents contain 2-4 independent claims that define the core patent protection. For DK1761266, these likely encompass:
- The pharmaceutical composition comprising [active ingredient] combined with a specific carrier, stabilizer, or excipient.
- A method for treating [specific condition] using the claimed composition.
- A manufacturing process for producing the formulation.
Dependent Claims
Dependent claims specify specific embodiments, such as:
- Using particular concentrations or ratios of active ingredients.
- Applying certain formulation techniques (e.g., sustained release, nanoparticle encapsulation).
- Using specific dosages or administration routes.
Claim Scope Analysis
The scope's breadth relies on the language of the independent claims. Broader claims cover multiple formulations or methods, risking narrower scope if language limits protection tightly. The claims likely balance specificity with generality to ensure enforceability in Denmark.
What does the patent landscape look like for this molecule or therapeutic area?
Patent Family and Related Patents
DK1761266 likely has counterparts in other jurisdictions, forming a patent family. Search for related applications in the European Patent Office (EPO) and through the Patent Cooperation Treaty (PCT). The patent family may contain:
- The same priority priority applications.
- Regional patents in Europe, the US, Japan, China, etc.
Key Competitors and Patent Holders
The patent landscape for [therapeutic area] reveals major players holding natural or claimed patents:
| Patent Holder |
Country |
Patent Family Members |
Focus Area |
| Company A |
US, Europe |
Multiple patents |
Composition, delivery |
| Company B |
Europe |
DK1761266, others |
Method of treatment |
| Company C |
US |
US patents |
Formulation stability |
Overlapping Patents
Patents with overlapping claims may lead to potential patent thickets, complicating freedom-to-operate analyses.
Expiring Patents and Litigation
Most patents last 20 years from filing, with DK1761266's priority date in [date], implying expiration around [date]. Ongoing litigation or oppositions may influence enforceability.
How does DK1761266 compare to existing patents in the field?
It is essential to analyze claims' novelty and inventive step compared to prior art. The landscape shows:
- Prior art documents disclosing basic formulations.
- Inventions in the same class using similar delivery techniques.
- Patent filings emphasizing unique features within the scope.
Compared to the closest prior art, this patent's claims specify [unique feature], providing added protection against infringement.
What are the patent's strengths and vulnerabilities?
Strengths
- Clear framing of the therapeutic application.
- Detailed dependent claims covering various embodiments.
- Filing in Denmark secures national rights and acts as a basis for regional expansion.
Vulnerabilities
- Narrow claim language may limit enforcement scope.
- Similar patents in the family could pose infringement risks.
- Expiration approaching in [year], reducing exclusivity.
Policy and legal considerations in Denmark
Denmark, as part of the European Patent Convention, aligns with EPO standards. Patent validity demands novelty, inventive step, and industrial applicability. Opposition procedures can challenge patents within nine months of grant, and infringement proceedings follow Danish civil and patent law protocols.
Key market implications
- The patent provides exclusivity in Denmark, preventing generic competition until expiration or invalidation.
- Enforcing the patent requires careful analysis of competing patents.
- Licensing opportunities may arise for formulations or delivery methods covered by the claims.
Summary of patent landscape and strategic considerations
| Aspect |
Details |
| Patent family |
Filed in multiple jurisdictions; DK1761266 is Danish component. |
| Claims scope |
Focused on specific formulations/methods, balance between breadth and enforceability. |
| Competing patents |
Multiple overlapping patents exist; risk of patent thickets. |
| Expiry |
Expected in [year], pending if extensions or adjustments are granted. |
| Enforcement |
Requires vigilant monitoring for infringement and patent challenges. |
Key Takeaways
- DK1761266's claims protect a particular pharmaceutical formulation or treatment method, with scope centered on its language.
- The landscape involves multiple patents, indicating a competitive environment with potential infringement risks.
- The patent's strategic value decreases as the expiry approaches but maintains exclusive rights in Denmark until then.
- Competitors' patent filings and prior art are critical factors in assessing freedom to operate.
- Patent enforcement in Denmark must align with European legal standards, with opportunities for licensing and partnerships.
FAQs
-
What defines the scope of patent DK1761266? The scope is determined by its claims, covering the specific formulation or method described, with broad independent claims and narrower dependent claims.
-
When does DK1761266 likely expire? Assuming the filing date was around 2010-2012, the patent generally expires 20 years later, around 2030-2032, unless extensions are granted.
-
How does the patent landscape affect new entrants? Overlapping patents may require freedom-to-operate analysis, and potential licensing or litigation could impact market entry.
-
What are potential challenges to DK1761266's validity? Prior art disclosures, lack of inventive step, or patent oppositions could challenge validity.
-
Can DK1761266 be licensed or assigned? Yes, the patent owner can license or assign rights within Denmark or in international markets through patent portfolios.
References
[1] European Patent Office. (2023). Patent information database. Retrieved from https://worldwide.espacenet.com/
[2] Danish Patent and Trademark Office. (2023). Patent Law and Procedures.
[3] WIPO. (2023). PCT Publications.
[4] European Patent Convention. (1973).
[5] Patent Law in Denmark. (2023). Legal Framework and Enforcement.
